Abstract

Background: Multiple myeloma is a hematological cancer, characterized by the proliferation of malignant plasma cells It is manifested through anemia, bone pain, and renal failure. Objectives: To evaluate the treatment outcomes of patients with multiple myeloma using a multi-chemical regimen at the Department of Clinical Hematology, Thai Nguyen National Hospital. Methods: A descriptive cross-sectional study was conducted on 29 patients diagnosed with multiple myeloma and treated with a multi-chemical regimen at the Department of Clinical Hematology, Thai Nguyen National Hospital from January 2022 to October 2022. Results: The proportion of anemia decreased from 79.3% to 14.5%, the number of patients with ostealgia decreased from 96% to 18.5%. The amount of Hb increased from 91.3 g/l to 112.1 g/l. Blood protein, globulin and IgG, pathological IgA, sFLC, β2 microglobulin all decreased. The proportion of remission, with good partial remission, with partial remission, and with no response to treatment were: 44.83%, 34.48%, 13.8%, and 6.89% respectively. Peripheral nerve complications predominated, accounting for 62.09%. 10.34% had got shingles. 13.8% was recorded with diarrhea. 6.89% had increased glucose. Thrombocytopenia at grade 3-4 and leukopenia at grade 3 made up 3.44%. Conclusions: VTD protocol has improved the condition of patients with multiple myeloma (clinically and subclinically), though accompanied by mild side effects.